Loading...
Loading...

Medical-Grade Weight Loss - FDA-Approved Mechanism
Semaglutide is a GLP-1 receptor agonist that regulates appetite, insulin sensitivity, and glucose metabolism. Clinical trials show average 15-20% body weight reduction over 68 weeks. Mimics natural incretin hormones for sustainable weight loss.
Inject subcutaneously once weekly, same day each week. Rotate injection sites (abdomen, thigh, upper arm). Store refrigerated 2-8°C.
Titration protocol: Start 0.25mg weekly for 4 weeks, increase to 0.5mg for 4 weeks, then 1mg, then 1.7mg, up to 2.4mg maximum. Slow titration minimizes GI side effects.
Reduces hunger and food cravings through GLP-1 receptor activation
Initial effects within first month
Research Studies
Enhances glucose metabolism and reduces insulin resistance
Initial effects within first month
Reduces cardiovascular risk factors and improves metabolic health markers
Initial effects within first month
Janoshik Analytical Laboratory
Third-Party Verified
All results independently tested and verified by accredited laboratories.
No FAQs available yet. Please contact us if you have questions.